embed embed share link link comment comment
" type="application/x-shockwave-flash" allowfullscreen="true" width="425" height="344">
Embed This Video close
Share This Video close
bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark
embed test
Rate This Video embed
1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...
Tags For This Video tags
rate rate tags tags related related lights lights

China’s Innovent Biologics May Look Into M&As, CFO Says

Ronnie Ede, executive director and chief financial officer of Jiangsu, China-based Innovent Biologics Inc., which develops and manufactures medicines for diseases such as cancer, discusses the company’s strategy and outlook. Innovent said last month the National Medical Products Administration of China has accepted a supplemental new drug application for sintilimab injection as second-line therapy for lung cancer by the company and Eli Lilly. Ede speaks on “Bloomberg Markets: Asia.”